Tag: AbbVie

Mergers and Acquisitions

AbbVie and Anima Biotech Partner on Discovery and Development of mRNA Biology Modulators

January 18, 2023

Via: Biopharm International

AbbVie and US-based Anima Biotech (Anima) have formed a collaboration to discover and develop messenger RNA (mRNA) biology modulators for three targets across oncology and immunology. In the collaboration, Anima will use its mRNA Lightning technology platform to discover novel […]

Pricing, Regulations

AbbVie and Eli Lilly leave UK’s voluntary drug pricing agreement

January 17, 2023


The companies will now come under the alternative statutory scheme imposed by the government through law, demonstrating what the ABPI describes as ‘the depth of feeling that the current voluntary scheme is damaging the UK life sciences industry’. Introduced in […]

Mergers and Acquisitions

AbbVie and Anima Biotech collaborate on mRNA biology modulators

January 11, 2023


The partners will use Anima’s mRNA Lightning platform to discover novel mRNA biology modulators for the collaboration targets, with AbbVie gaining exclusive rights to licence, further develop and commercialise the resulting programmes. In exchange, an upfront payment of $42m will […]

FDA, Regulations

AbbVie claims key approval for Vraylar in depression

December 19, 2022

Via: Pharmaphorum

The approval makes Vraylar (cariprazine) the ” first and only” dopamine and serotonin partial agonist indicated as an add-on therapy for depression, according to AbbVie, adding to the lengthening list of therapies for patients who struggle to control mood with […]

Clinical Trials, Mergers and Acquisitions, Research and Development

AbbVie sheds autoimmune disease drug in blow to partner Inventiva

October 31, 2022

Via: Pharmaphorum

The decision to drop the oral ROR gamma inverse agonist – also known as ABBV-157 – came after analysis of a recently concluded nonclinical toxicology study, according to an Inventiva statement, in which the company said it does not expect […]

Mergers and Acquisitions

AbbVie acquires DJS for $255m cash, fortifies immunology pipeline

October 21, 2022

Via: Pharmaphorum

The acquisition of DJS Antibodies, a privately-held UK-based biotechnology company dedicated to discovering and developing antibody medicines that target difficult-to-drug disease-causing proteins – such as G protein-coupled receptors (GPCRs) – will extend AbbVie’s present discovery research capabilities, through DJS’ proprietary […]


AbbVie cuts Alzheimer’s alliance with Alector in half

July 11, 2022

Via: Pharmaphorum

AbbVie first bought in to the programme with a $205 million upfront payment five years ago, attracted by the potential to use checkpoint inhibitors to try to reproduce in neurology the sometimes stunning results achieved with the class in oncology. […]

FDA, Regulations

FDA Approves AbbVie’s Qulipta

September 30, 2021

Via: Biopharm International

AbbVie announced that FDA approved Qulipta (atogepant) for the preventive treatment of episodic migraines in adults on Sept. 28, 2021. According to a company press release, Qulipta is the first and only oral calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) […]

Cell and Gene Therapy, Industry

AbbVie bets big on a gene therapy for eye diseases

September 13, 2021

Via: Biopharma Dive

While estimates vary, AMD is thought to affect a large number of people. A study published in 2014, for instance, projected the patient population globally would hit 196 million in 2020 and grow to 288 million by 2040. Among those […]